Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
Contract manufacturing
Own product Manufacturing
R&D
Pipeline
ISM®
Glycomics
Multilayer technologies
Shareholders and Investors
General information on the Company
How to contact the Company
Shares and share capital
Investor Agenda
Dividends
Public offerings and admission to trading
Public tender offers
Bylaws
Relevant events
Shareholders agreements
Significant interests and treasury shares
Analyst Coverage
Financial and economic information
Regular Public Information
Audit Report, Audited Annual Financial Statements (individual and consolidated), Management Report and Annual Report
Public information sent to regulatory bodies, other than information prepared under Spanish regulations
Rating
Average payment period to suppliers
Share information
Corporate Governance
Regulations of the Shareholders Meeting
General Shareholders' Meeting: exercising the right to information
Notice and Agenda of the Meeting
Full texts of the proposed resolutions to be taken and the documentation available to the shareholder prior to the Meeting
Shareholders request for information or clarification
Proxy voting
Distance voting at General Meetings
On-line attendance
Information on the contents of past General Meetings
Board of Directors
Regulations of the Board of Directors
Annual Corporate Governance Report
Director compensation
Board Committees
Internal rules of conduct relating to trading in the securities market
Shareholder Forum
Corporate Policies
Contact
Information for Investors
Annual Reports
Press Releases
Latest results
Information for investors
Webcasts and Presentations
Contact
CSR
Mission, vision and values
Relations with Stakeholders
Commitment to Society
Commitment to the environment
Commitment to the employees
Quality, Environment, Safety and Health
Media
FAQS
News
Contact
Work with Us
INTRANET
Home
First quarter 2020 results presentation
First quarter 2020 results presentation
Find out more …
FAQs
News
Contact
Operating income, growth figures, profitability and how our products have behaved.
Wed, 13/05/2020 - 00:00
Descargar noticia
Download PDF
Comments
Add new comment
Your name
Subject
Comment
*
More information about text formats
Text format
Comment User
Plain text
Comment User
Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
Lines and paragraphs break automatically.
Plain text
No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Math question
*
3 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Related
News
13/01/2021
ROVI completes the manufacture of the first batches of Moderna vaccine
27/11/2020
The Journal npj Schizophrenia Publishes the Results of the PRISMA-3 Study of the Efficacy and Safety of Doria® in Schizophrenic Patients
24/11/2020
2020 Capital Markets Day presentation
Comments
Add new comment